Thread: Prosavin (gene therapy) trial kicks off ...
View Single Post
Old 12-13-2007, 03:01 PM
Stitcher's Avatar
Stitcher Stitcher is offline
Magnate
  
Join Date: Aug 2006
Posts: 2,136
15 yr Member
Stitcher Stitcher is offline
Magnate
Stitcher's Avatar
 
Join Date: Aug 2006
Posts: 2,136
15 yr Member
Default
As a participant in the CERE-120 trial, I would like to know how this European-based trial gene-therapy differs from CERE-120 (Neuturin) or glutamic acid decarboxylase (GAD) gene? GAD recently completed Phase I.

Is this pre-trial data, or Phase I data...doesn't seem clear in the press release. The long-term post-Phase I data for Neuturin appears to have the same effect as ProSavin. Or am I wrong in my assumption? It appears to say that Phase I/II will commence.
Quote:
Long-term efficacy data in the industry-standard preclinical model of Parkinson’s disease have shown that ProSavin induces almost complete recovery of movement function and other behavioural measurements. In this model, the therapeutic effect of ProSavin following a single administration has been maintained for over 24 months with no diminishment.
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall

I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller
Stitcher is offline   Reply With QuoteReply With Quote